Patrys (ASX:PAT)

Executive Summary

Patrys Limited is an Australian clinical-stage biotechnology company advancing two distinct therapeutic programs: a proprietary intravenous formulation of quetiapine (RLS-2202) for the treatment of acute delirium, and a deoxymab antibody platform targeting oncology, inflammatory, and autoimmune diseases. The company is publicly traded on the ASX under ticker PAT and is currently conducting Phase 1/2 clinical trials for RLS-2202, aiming to address a significant unmet need in hospital settings where acute delirium complicates patient recovery. Its antibody platform, based on deoxymab technology, offers potential versatility across multiple indications, though it remains in preclinical and early-stage development. Patrys has a focused strategy of leveraging internal R&D and potential partnerships to accelerate clinical validation and commercialization. With a lean operational structure and a dual pipeline, the company presents a high-risk, high-reward profile typical of early-stage biotechs. Key near-term milestones include the completion of ongoing trials for RLS-2202 and further characterization of the deoxymab platform. While the pipeline is early, Patrys addresses large markets—delirium affects millions of hospitalized patients annually—and its platform could unlock differentiated antibody therapeutics. The company's progress will hinge on successful clinical data, regulatory clarity, and securing strategic collaborations.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Interim Data for RLS-2202 in Acute Delirium40% success
• Q1 2027Preclinical Proof-of-Concept Data for Deoxymab Platform in Oncology50% success
• Q2 2027Licensing or Collaboration Agreement for Deoxymab Platform25% success